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high-prevalence geographic areas of the world such as 
parts of Asia and Africa7-11. Transmission can be prevent-
ed by a 95% effective vaccine, which has been available 
since 19828.
Natural History of Hepatitis B
The conversion of acute to chronic hepatitis depends on 
age and immune response at the onset of infection9,10. 
Hepatitis B e antigen (HBeAg) status can be character-
ized on the basis of the course of HBV infection. Immuno-
logic tolerance to HBV occurs during perinatal infection 
or in early childhood and lasts for a lifetime10. Although 
the mechanisms involved in immune-tolerance to HBV 
remain unclear, minor HBV-associated liver injury de-
spite high-level HBV replication indicate immune toler-
ance to HBeAg12.
Introduction
Hepatitis B is a global public health issue due to its 
worldwide presence, and the World Health Organization 
(WHO) estimates that two billion people in the world are 
infected with hepatitis B virus (HBV). Chronic carriers 
are estimated to be from 300 to 500 million persons. HBV 
can cause acute hepatitis leading to acute liver failure in 
some cases, while about 5% become chronic carriers and 
are at risk for developing liver cirrhosis and hepatocar-
cinogenesis1. WHO estimates that between 500,000 and 
700,000 people in the world die each year from HBV infec-
tion and the consequences of the condition2-5. Prevalence 
and modes of transmission vary from one country to an-
other; HBV infection poses the greatest problem in devel-
oping and poor countries1-6. Primary HBV infections occur 
at much higher frequencies and at much earlier ages in 
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sex workers, and other people with high risk sexual behav-
iors are at particularly high risk for infection. In hetero-
sexuals, factors associated with an increased risk of HBV 
infection include duration of sexual activity, number of 
sexual partners, history of sexually transmitted diseases, 
and a positive serology for syphilis23.
In areas where the prevalence of HBV infection is low, 
occupational blood exposure predominates2-5,13,16,24-27.
The aim of this report is to describe epidemiological 
characteristics and preventive measures implemented for 
the prevention and suppression of HBV in Croatia.
Methods
Data from the National Institute of Public Health on 
infectious disease reports28, and data from legal acts about 
preventive measures against hepatitis B infection were 
analyzed. The County of Split – Dalmatia has been used 
for comparison, because in this county hepatitis B infec-
tion was major public health problem.
The data used in this report are from the Croatian 
National Institute of Public Health and are regularly 
cited in publications like the Croatian Health Service 
Yearbook and Epidemiological News from 1996 to 2012. 
Incidence and prevalence have been calculated for the 
number of inhabitants according to the 2001 and 2011 
Census data. According to the 2001 Census, 4,437,460 
people live in the Republic of Croatia and 463,676 people 
live in the County of Split-Dalmatia. According to the 2011 
Census, 4,284,889 people live in the Republic of Croatia 
and 454,798 people live in the County of Split-Dalmatia28. 
Hepatitis B surveillance and reporting conducted in the 
County of Split-Dalmatia do not differ from the surveil-
lance strategies at the national level.
Data on the number of the infected, the number of HBV 
carriers, and the age and sex structure of the infected 
were obtained from the Epidemiology Department of the 
Croatian National Institute of Public Health as reported 
by physicians’ offices.
Acute hepatitis B is reported on the basis of several 
clinical outcomes (e.g. fatigue, with or without jaundice, 
increase in serum alanine aminotransferase (ALT) levels 
by more than 2.5 times) and serological test results which 
include HBsAg-positive or IgM anti-HBc positive and 
anti-Hepatitis A virus (anti-HAV) IgM negative find-
ings2,3,16,25.
Persons who have had HBsAg-positive results twice 
within a period of six months are reported as chronic virus 
carriers. The inactive carrier is an HBsAg-positive person 
with undetectable viremia (HBV DNA negative) and nor-
mal transaminases.
Results
Hepatitis B morbidity in Croatia
In the period from January 1, 1995 to December 31, 
2012, 2,939 new cases of acute HBV infections were re-
After seroconversion, most patients remain negative 
for HBeAg and positive for anti-HBe antibody. This phase 
reflects relatively higher immunologic tolerance early and 
relatively lower tolerance later in the natural history of 
chronic HBV infection acquired early in life. This phase 
is usually referred to as the »inactive carrier state«10,12. 
Hepatitis B’s antigen (HBsAg) can still be found in the 
blood of patients of one part of infected patients even after 
recovery but with no other symptoms of the disease (the 
so-called healthy inactive HBsAg carriers). In some pa-
tients who have recovered, co-infection with the wild-type 
virus and mutations has been shown4,13-16. The number of 
inactive carriers in certain countries and larger geograph-
ic areas is a good indicator of HBV infection preva-
lence4,13,16-19.
HBeAg-reactive chronic HBV infection is followed by 
high-level HBV replication, and spontaneous sero-conver-
sion from HBeAg-positive to antibody (anti-HBe)-positive 
infection coincides with a reduction in HBV replication 
and clinical improvement20,21.
Routes of Transmission
The predominant transmission of HBV infection is 
through contact with infected blood and serous fluids8. 
Saliva can also be infectious, and epidemiological studies 
suggest human bite as possible route of transmission22. 
Risks for parenteral or mucosal transmission includes in-
jection drug use, transfusion and dialysis, acupuncture, 
working in health care settings, tattooing, household con-
tacts, and others who are likely to come into contact with 
potentially infected blood and blood products6,12,13,16,23.
HBV can be transmitted through infected blood or 
body fluids that enter through mucous membranes, sexu-
ally, and perinatally8,9. The highest concentrations of virus 
are in blood and serous fluids8.
Transmission of HBV from carrier mothers to their 
babies can occur during the perinatal period, and appears 
to be the most important factor in determining the preva-
lence of infection in high endemic areas, particularly in 
China and Southeast Asia6,7. Transmission mostly occurs 
during delivery (perinatally), seldom intrauterinally (up 
to 10%) and in the early post-delivery period14. Infection 
of infants with HBV is efficient: 70% – 90% will become 
infected from perinatal exposure to a mother positive for 
both HBsAg and HBeAg, while 20% of infants will become 
infected from a mother if positive for only HBsAg. A high 
frequency (>90%) of these infected infants will become 
chronic carriers due to immaturity of the infant’s immune 
system, although it seems that the final outcome does not 
depend only on the infant’s immunocompetence and the 
level of the mother’s viremia, but on the heterogenetic 
characteristics of the virus6,8,13-16,24.
The sexual transmission of hepatitis B is a major source 
of infection in all areas of the world, and is the predominate 
mode of transmission in areas where the prevalence of 
HBV infection is low, such as North America and Western 
Europe4-7,11,13,16,24-27. Sexual partners of injection drug users, 
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which, among other intervention activities, provided 
free needles and syringes. The interventions imple-
mented through »Help« resulted in an evident decrease 
in the number people infected with hepatitis B, as il-
lustrated in Figure 1.
TABLE 1
THE NUMBER OF REPORTED CASES OF ACUTE HBV INFEC-
TION AND CHRONIC HBV CARRIERS IN CROATIA DURING 
THE 1996 – 2012 PERIOD





1995  214/1* 4.60 194 4.37
1996  198 4.46 169 3.81
1997  263/1* 5.81 250 5.63
1998  211/1* 4.73 200 4.51
1999  215/1* 4.75 228 5.14
2000  189 4.42 169 3.81
2001  200 4.60 310 6.99
2002  205 4.87 221 4.98
2003  180 3.85 159 3.58
2004  217 4.89 176 3.97
2005  164 3.70 164 3.70
2006  148 3.33 129 2.91































*died; source: Croatian Health Service Yearbook 2012; Croatian 
National Institute for Public Health
Fig. 1. Morbidity per 100,000 and linear trend of newly reported 
HBV cases* in Croatia and Split-Dalmatia County during the 
1995-2012 period. Source: Croatian National Institute of Public 
Health.
Fig. 2. Rate of reported cases of HBV carriers (chronic cases) 
and linear trend (calculated by Excel (Microsoft, 2005)) in 
Croatia and Split-Dalmatia County, 1995-2008. Source: 
Croatian National Institute of Public Health.
ported in Croatia, six of whom died (case fatality rate 
0.2%). During the same period, 3,030 chronic HBV in-
fected carriers were reported. The number of reported 
cases of acute HBV infection and chronic HBV carriers in 
Croatia during the 1995 – 2012 period can be seen in 
Table 1. During this study period, we can see a signifi-
cantly lower number of cases in the recent years, and the 
average number of 163 cases.
Comparison of hepatitis B morbidity in the County 
of Split-Dalmatia and Croatia
The morbidity dynamics of hepatitis B was analyzed 
in the County of Split-Dalmatia, an area with different 
socioeconomic characteristics as compared to the rest 
of Croatia. During the period of the Croatian War of 
Independence from 1991 to 1995, intravenous drug 
abuse was a significant problem in this county where 
10% of the country’s population lives. The local com-
munity recognized the problem and in cooperation with 
non-governmental organizations (NGOs) started the 
»Help« program in 1995 for injection drug addicts 
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HBV chronic carriers
The annual number of reported HBV carriers, which 
on average is 168 persons in Croatia, varied significantly 
during the period studied when compared to the average. 
For example, 310 cases were reported in 2001 and 98 in 
2012. The reason why a greater number of HBV carriers 
was reported in 2001 is because HBV (and HCV) testing 
was performed on all persons who received hem dialysis 
that year. In the period studied, there is a significant de-
cline trend in the number of chronic virus carriers in 
Croatia, while in the County of Split-Dalmatia the trend 
shows a slight increase during recent years, Figure 2.
Number of hepatitis B infected by month
No significant differences exist in the number of those 
diseased by month, except for a slightly smaller number 
of diseased persons in August and other summer months 
in general, which can be attributed to the summer holiday 
season when hepatitis B reporting is less frequent. With 
regard to transmission, seasonal occurrence is not to be 
expected with hepatitis B. The number of HBV cases by 
month in Croatia and Split-Dalmatia County, from 1995 
to 2012 is shown in Figure 3.
Age and sex structure of hepatitis B diseased 
patients
Hepatitis B infection in Croatia is recorded in all age 
groups. The greatest number of cases is recorded in the 20 
– 29 years of age group. In the county of Split-Dalmatia 
morbidity is somewhat greater in that age group – 51.8 per 
100,000. In Croatia, the same age group accounts for 26.8 
per 100,000 of the diseased. The incidence of HBV cases 
among different age groups (age specific rate) in Croatia 
and Split-Dalmatia County from 1995 to 2008 period can 
be seen in Figure 4.
In terms of sex structure, the number of male patients 
is greater in both Croatia and the County of Split-Dalma-
tia. In Croatia, 40.7 per 100,000 women are infected, 
while in the County of Split-Dalmatia women account for 
one-third of the infected at 33.2 per 100,000. Men are 
mostly infected between the ages of 20 and 29. The great-
est number of infected women is in the 15-19 years of age 
group (Figure 5).
Case fatality rate
In the period observed the average case fatality rate 
for hepatitis B in Croatia was 0.2% : 6 out of the 2,939 
diseased patients died. One death was recorded in 1995, 
1997, 1998, 1999, 2010 and 2011 respectively. In the past 
ten years there have been no deaths due to HBV infection 
in the County of Split-Dalmatia.
Incidence of HBsAg-positive markers in volunteer 
blood donors
The incidence of HBsAg-positive blood donors is a good 
but indirect indicator of the prevalence of inactive HBV 
Fig. 3. Number of HBV cases by month in 
Croatia and Split-Dalmatia County, 
1995-2012. Source: Croatian National 
Institute of Public Health.
Fig. 4. Incidence of HBV cases (age specific rate) in Croatia and 
Split-Dalmatia County, 1995-2008. Sources: Croatian National 
Institute of Public Health and Institute of Public Health in 
Split-Dalmatia County.
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Fig. 5. Average incidence of HBV by age and 
sex, Croatia and Split-Dalmatia County, 
1995-2008. Sources: Croatian National 
Institute of Public Health and Institute of 
Public Health in Split-Dalmatia County.
Fig. 6. Prevalence (%) of HbsAg-positive markers in volunteer 
blood donors in Croatia 1993-2007 and Split-Dalmatia County 
1999-2011. Sources: Croatian Health Service Yearbook 2012 
and Department of Blood Transfusion, Clinical Hospital Split.
TABLE 2
THE PERCENT OF INFANTS AND SCHOOL CHILDREN 
VACCINATED AGAINST HBV INFECTION, CROATIA, PERIOD 
2007-2012








Source: Croatian Health Service Yearbook 2012; Croatian National 
Institute for Public Health
carriers in a population. The prevalence of HBsAg-positive 
blood donors in Croatia has been constantly decreasing 
during recent years. The prevalence (%) of HbsAg-positive 
markers in volunteer blood donors in Croatia from 1993 
to 2011 and the County of Split-Dalmatia from 1999 to 
2013 is illustrated in Figure 6.
Data on the prevalence of HbsAg-positive blood donors 
in the County of Split-Dalmatia from 1999 to 2013 show 
higher values than the average found in the Republic of 
Croatia, which is probably a consequence of a greater num-
ber of infected patients in the past.
Compulsory hepatitis B vaccination for adults and 
children in Croatia 
Table 2 shows the number of infants and school chil-
dren vaccinated against HBV infection during 2007- 2012 
period. Starting in 2000, all children aged 11 – 12 years 
were required to receive the hepatitis B vaccine. A routine 
infant vaccination schedule was added in 2007, resulting 
in an increase in the number of scheduled and vaccinated 
persons. Vaccination coverage remained over 90% from 
2007 to 2012.
Discussion
In Croatia, high-risk groups for HBV infection include 
injection drug users, household contacts, sexual partners 
of HBV carriers, health care workers, patients receiving 
chronic hemodialysis, and organ transplant recipients. In 
addition, medical and dental interventions, tattoos and 
acupuncture are not to be excluded16,24-26.
It is interesting to note that females are younger than 
males when infected with HBV in Croatia – between the 
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ages of 15 and 19. At this period in life they probably get 
infected through sexual transmission as the average age 
of girls’ first sexual intercourse is 15 and usually with a 
partner several years older than themselves29.
Numerous HBV prevention measures are employed in 
Croatia, but most public health research experts and au-
thorities agree that vaccination is the most efficient form 
of prevention6,13,27. Vaccination against hepatitis B has 
been mandatory since 1992 for all persons exposed to in-
fection in Croatia30. The hepatitis B vaccine available in 
Croatia is a highly effective and safe vaccine produced 
through the genetic engineering of yeast fungi31. HBV has 
a stable, long-enduring covalently closed circular DNA 
structure which means that the virus has low mutagenic-
ity levels, assuring vaccine effectiveness2-3,32. However, the 
emergence of naturally occurring mutations may be a po-
tential problem for the current HBV vaccine, as the muta-
tions change the characteristics of HBsAg enabling the 
mutated virus to »escape« from the immunological re-
sponse. It seems that such mutations are rare at the mo-
ment, but if they occur frequently, then necessary chang-
es in the HBV vaccine and diagnostic protocols will be 
needed2,16,24.
A Rulebook on the methods of implementing immuni-
zation, seroprophylaxis, and chemoprophylaxis against 
contagious diseases stipulates that vaccination is manda-
tory for all healthcare workers, newborns of HBsAg-posi-
tive mothers, patients on hemodialysis, family contacts of 
HBsAg-positive persons, mental institution staff, intrave-
nous drug users and patients suffering from hemophilia 
and leukemia33,34.
Universal vaccination of school children (11 – 12 years 
of age) not previously vaccinated with the hepatitis B vac-
cine started in 200028. In 2007, following a recommenda-
tion from the World Health Assembly for global HBV vac-
cination, the Croatian National Institute of Public Health 
approved universal vaccination of newborns and intro-
duced a routine infant schedule. In addition, the imple-
mentation of selective vaccination against hepatitis B 
started in 1992 did not yield a reduction in prevalence, 
creating a stimulus for universal vaccination of all new-
borns in Croatia. In 2007 94.4% of infants/school children 
were vaccinated against hepatitis B28. For infants with 
normal immune status, hepatitis B vaccine is given in 
three doses at month 0, 1, and after 6 months. Children 
with normal immune status also receive three doses of the 
vaccine with the second and third doses given 1 to 3 and 
2 to 17 months respectively after the first. Newborns born 
to HbsAg-positive mothers are protected after one dose of 
HBIG (human hyperimmune gamma globulin) and by fast 
(several hours after birth) scheme vaccination recom-
mended at 0, 1, 2, and 12 months. Fast vaccine application 
and high doses of HBIG ensure protection of 94% of new-
borns from HBsAg whose mothers are HBsAg-positive. In 
half of these, 6% of newborns will become chronic carriers 
despite vaccination due to intrauterine infection before 
birth. For these infants, any postnatal attempt at vaccine 
protection would be ineffectual6,13,33,34.
According to the WHO recommendations, a booster 
dose of hepatitis B vaccine can be given 15 years after the 
first dose because completely immunized persons are pro-
tected until that time, even if the titer of antibodies cannot 
be measured because the immunological memory secures 
a protective recall response after HBV exposure3,5,35. On 
the other hand, the European Consensus Group on hepa-
titis B immunity recommends that booster doses are un-
necessary in immunocompetent persons following a com-
plete course of vaccination36. The latest Croatian Rulebook 
on the methods of implementing immunization, seropro-
phylaxis, and chemoprophylaxis against contagious dis-
eases does not include the possibility of booster vaccina-
tion after a fully implemented immunization34.
We assume that in certain counties of Croatia intrave-
nous drug abuse plays a significant role in spreading 
hepatitis B, but no studies to date have explored intrave-
nous drug abuse as a major mode of transmission on a 
county level37. From epidemiological data, people aged 20 
– 29 are a high-risk group for HBV infection through injec-
tion drug use. Based on these findings, additional educa-
tional and prevention programs should be created to tar-
get this high-risk group with the realization that this 
group lacks awareness of the risk and consequences of 
hepatitis and are predicted to have low vaccine completion 
rates8,37. In order to achieve complete protection against 
hepatitis B, vaccination efforts for infants, adolescents, 
and high-risk groups will continue38. The effect of any vac-
cination efforts will be evident from a decrease in the in-
cidence and prevalence of HBV infection after a number 
of years, therefore a final evaluation of intervention suc-
cess can only occur in the future. Decline of incidence and 
prevalence of hepatitis B in Croatia is already visible. In 
countries such as Italy and the U.S. the incidence of acute 
hepatitis B has declined dramatically during the past de-
cade after the implementation of hepatitis B vaccination 
programs, particularly among persons in younger age 
groups39,40. To assess the immune status of vaccinees, an 
evaluation of vaccination impact could be performed by 
measuring HBsAg prevalence in cohorts of vaccinated 
children. Currently, there are no data available on the 
impact of infant or childhood hepatitis B vaccination pro-
grams in Croatia. In Croatia comprehensive, legally stip-
ulated measures (Public Protection from the Infectious 
Diseases Act and various rulebooks) are being implement-
ed with the aim of combating and preventing hepatitis B 
infection – the screening of blood donations, mandatory 
testing for all pregnant women, vaccination and seropro-
phylaxis in infants born to HBsAg-positive mothers, vac-
cination according to the immunization schedule and ac-
cording to epidemiological indications, as well as all other 
preventive measures in medicine and dentistry. A l-
though vaccination is mandatory for all healthcare work-
ers33,34 in Croatia, the percentage of coverage is unsatisfac-
tory. Some authors have tried to look into the possible 
reasons why hepatitis B vaccination is avoided by health-
care workers and have come to the conclusion that fear is 
a factor present among health workers due to a lack of 
information about the vaccine41,42.
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Research has shown that until 1990, 20% of all pa-
tients hospitalized for acute hepatitis B in the Zagreb area 
were healthcare workers from high-risk groups, mostly 
nurses, and there has been a significant decrease in this 
percentage since the introduction of vaccination against 
hepatitis B in 198741. Still, vaccination does not seem to 
extend to all healthcare workers. One study of a larger 
group of research subjects has shown that 58.1% of all 
healthcare workers are not vaccinated for different rea-
sons43.
The Act on blood and blood products established by the 
Ministry of Health and Social Welfare stipulates that the 
Croatian Institute of Transfusion Medicine should keep a 
record of blood donors. In the Blood Donors Registry, data 
on persons who temporarily or permanently cannot donate 
blood are recorded separately. Medical information on 
blood donors, including test results are confidential and 
must be protected from unauthorized use. The Blood Do-
nors Registry is a part of the national system for transfu-
sion and must be available to all healthcare institutions 
that collect blood44. In Croatia disease screening of do-
nated blood is mandatory, and monitoring has shown a 
decrease in the risk of transmissible infections through 
transfusion44,45.
It was relatively early that a needle exchange program 
began in Split-Dalmatia County for intravenous drug us-
ers37. A non-governmental organization called ‘Help’ start-
ed operating in the Split area in 1995 to 1996. The main 
activity of this organization is to educate and counsel in-
travenous drug users, most of all through free exchange 
of needles and syringes, resolve their socio-legal problems, 
provide free and anonymous testing, refer them to treat-
ment, and provide psychological support. As far as the rest 
of Croatia is concerned, »Help« implements the needle ex-
change and counseling program in the area of twenty cit-
ies in Croatia 37.
No published data exist on the number of intravenous 
drug users in Croatia who had or still have chronic HBV 
infection. However, according to unpublished data from 
the Epidemiology Department of the Croatian National 
Institute of Public Health, in the County of Split-Dalmatia 
40% of all intravenous drug users tested through ‘Help’ 
have markers of recovery from an HBV infection and 3.9% 
have chronic HBV infection. Estimated prevalence of HB-
sAg in injecting drug users in Croatia in the years 2007-
2008 is average 0.4% (from 0.0 to 0.8%). Estimated preva-
lence of anti HBc in injecting drug users in Croatia in the 
years 2007-2008 is average 36.6% (from 27.1 to 46%). 
WHO argues that injecting drug users (IDUs) are a key 
group that needs to be specifically targeted for prevention 
and treatment of viral hepatitis38.
Data from Slovenia show that 17.5% of intravenous 
drug users have suffered from HBV infection, and only 
2.5% are chronic virus carriers47. Research conducted on 
intravenous drug users in the U.S. shows that 4.7% have 
chronic HBV infection, while 32.3% have markers of hav-
ing recovered from an HBV infection48. Other research 
also conducted in the U.S. shows a high incidence of occult 
HBV infection (no circulating HbsAg present in the se-
rum) in intravenous drug addicts with hepatitis C virus 
(HCV) infection49.
Having considered the data found in the literature that 
up to 5% of intravenous drug users are HBsAg-positive, 
more than 3,000 are registered in the area of the County 
of Split-Dalmatia, and that in the Croatian register of 
patients treated for psychoactive substance abuse and/or 
addiction a total of about 35,000 persons50 were registered 
from 1976 to the end of 2012, we believe that in addition 
to extensive implementation of all preventive medical and 
dental measures, the »Help« program has probably con-
tributed to the decline in morbidity rates in the area of the 
County of Split-Dalmatia.
It is interesting that in Asian countries with a high 
prevalence of HBV chronic infection vertical transmission 
predominates, whereas in African countries acquired in-
fections are mainly from horizontal transmission13-16.
Universal testing of pregnant women for HBsAg was 
introduced in Croatia in 199934,37. However, research con-
ducted on a sample of 400 pregnant women in Split, the 
second largest city in Croatia, shows a low incidence of 
viral infection (0.75%)46.
Studies conducted by authors in the County of Osijek-
Baranja have shown that multiple household members 
living with one hepatitis B infectious person are more 
likely to be infected25. Therefore, to prevent this type of 
transmission other HBsAg-positive family members need 
to be reported, while members negative for HBsAg should 
undergo vaccination.
In men who have sex with men (MSM), a high serop-
revalence of HBsAg along with risky sexual behavior con-
tribute to a higher incidence of acute hepatitis B compared 
with the general population27,52. Data are not available 
regarding heterosexuals or MSM as high-risk groups for 
HBV in Croatia.
Conclusion
Thanks to the extensively implemented preventive 
measures and vaccination of adolescents and high-risk 
groups, the expected decrease in the prevalence of hepati-
tis B morbidity rates in Croatia did occur. Comprehensive 
vaccination (infants, adolescents, and high-risk groups) 
began in the year 2007. Studies from several immuniza-
tion programs initiated in other countries 15 years ago 
show a significant reduction in hepatitis B morbidity 
rates, but not the elimination of HBV infection. Therefore, 
in order to better understand the epidemiology of hepatitis 
B in Croatia, specific research of its characteristics in 
high-risk settings is needed, in line with WHO recom-
mendations. This would enable us to visualize certain 
peculiarities which would guide the development of coun-
ter-epidemic approaches aimed particularly at endangered 
target groups. Thus, along with the implementation of nu-
merous unique counter-epidemic measures at the nation-
al level, it would be possible to implement such measures 
that would decrease the incidence of new hepatitis B cases 
in high-risk settings.
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Limitations
The limitations of this report include the lack of sur-
veillance data on high-risk groups, such as MSM and 
health care workers. Therefore, interpretation of the find-
ings may not be extended to these groups. This report was 
funded by the Croatian Ministry of Science, Education, 
and Sport, project No 216-1080315-0289.
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EPIDEMIOLOŠKE KARAKTERISTIKE HEPATITISA B U HRVATSKOJ: REZULTATI PREVENCIJE
S A Ž E T A K
Ova studija pokazuje epidemiološke karakteristike te preventivne mjere uključene u prevenciju i kontrolu hepatitis 
B infekcije u Hrvatskoj. Analizirani su podaci obveznih prijava zaraznih bolesti kao i prijava smrti zbog zaraznih 
bolesti, trenutno stanje hepatitis B infekcije u Hrvatskoj te anketni podaci prikupljeni iz opće populacije. Prosječna 
prevalencija ove bolesti kod nas iznosi 3,67 na 100,000 godišnje. Pogođene su sve dobne skupine, uz zamjetno veći broj 
zahvaćenih u dobnim skupinama od 15-19 te 20-29 godina. Hepatitis B infekcija je 1,4 puta učestalija kod muškaraca. 
Kroz zadnjih osamnaest godina zabilježena je prosječna smrtnost od 0,2%. Incidencija HbsAg-pozitivnih darovatelja 
krvi je unutar raspona od 0,65% 1992.godine do 0,012% u 2011. godini. Najveći broj preventivnih mjera protiv hepatitis 
B infekcije u Hrvatskoj je propisan zakonom. Prijava akutnih i kroničnih nositelja je obvezna. Vakcinacija visoko rizičnih 
skupina započeta je 1992.godine, dok je obvezna vakcinacija novorođenčadi uvedena u obveznom kalendaru cijepljenja 
2007. godine. Obvezno je rutinsko testiranje krvi dobrovoljnih davaoca na prisustvo HbsAg antigena. Zahvaljujući nev-
ladinoj organizaciji ‘Pomoć’ osnovanoj kao potpora intravenskim ovisnicima a zajedno s programom ‘sanacije štete’ 1995.
godine dolazi do implementacije hepatitis B,C te HIV/AIDS prevencijskog programa. Kako bismo bolje razumjeli 
epidemiološke karakteristike hepatitis B infekcije u Hrvatskoj, potrebna su dodatna istraživanja o specifičnosti i din-
amici u malim sredinama, obzirom na različite načine širenja infekcije.
